Clonal antibodies for core protein of chondroitin sulfate proteoglycan

Proteoglycans: gene cloning

Aggrecan is a large proteoglycan that plays roles in numerous tissues during vertebrate development and adult life. The 6,327-nt chick aggrecan coding sequence had been determined from overlapping clones, but a full-length cDNA, needed for use in transgenic expression studies, had not been constructed. The strategy employed to do so was to generate two overlapping cDNA subfragments that shared a unique restriction site in the overlap and then join them at that site. These subfragments were obtained and cloned into the TOPO-TA vector pCR2.1. Digestion of the two constructs with the shared-site enzyme, XbaI, produced vector/5'-cDNA and 3'-cDNA fragments with XbaI-ends; these were ligated to produce the final full-length cDNA.

Domain organization, genomic structure, evolution, and regulation of expression of the aggrecan gene family

Proteoglycans are complex macromolecules, consisting of a polypeptide backbone to which are covalently attached one or more glycosaminoglycan chains. Molecular cloning has allowed identification of the genes encoding the core proteins of various proteoglycans, leading to a better understanding of the diversity of proteoglycan structure and function, as well as to the evolution of a classification of proteoglycans on the basis of emerging gene families that encode the different core proteins. One such family includes several proteoglycans that have been grouped with aggrecan, the large aggregating chondroitin sulfate proteoglycan of cartilage, based on a high number of sequence similarities within the N- and C-terminal domains. Thus far these proteoglycans include versican, neurocan, and brevican. It is now apparent that these proteins, as a group, are truly a gene family with shared structural motifs on the protein and nucleotide (mRNA) levels, and with nearly identical genomic organizations. Clearly a common ancestral origin is indicated for the members of the aggrecan family of proteoglycans. However, differing patterns of amplification and divergence have also occurred within certain exons across species and family members, leading to the class-characteristic protein motifs in the central carbohydrate-rich region exclusively. Thus the overall domain organization strongly suggests that sequence conservation in the terminal globular domains underlies common functions, whereas differences in the central portions of the genes account for functional specialization among the members of this gene family.

Aggrecan: A Target Molecule of Autoimmune Reactions

Aggrecan in cartilage forms aggregates with hyaluronan and link protein, embedded in a collagen network. It accounts for the compressive stiffness and resilience of the hyaline cartilage. Many forms of inflammatory arthritis were shown to be accompanied with aggrecan degradation and loss from the cartilage. The loss of this major component of cartilage renders the tissue more vulnerable when exposed to abrasive forces. Therefore, aggrecan degradation may significantly contribute to cartilage destruction in arthritis. Furthermore, fragments of degraded aggrecan are released during joint inflammation. Thus, molecules of an avascular, immune-privileged tissue (hyaline cartilage) may become accessible to the cells of the immune system. Similarly, there is a "leakage" of aggrecan fragments from cartilage during aging and after joint injury, which may also lead to autosensibilisation. Autoimmune reactivity to aggrecan can be detected in human joint diseases, as well as in animal models of arthritis. The epitopes involved in these processes are currently being identified. Recent data from work with mice suggest a strong immune response focused to the N-terminal G1 domain of aggrecan that leads to arthritis and spondylitis.

Cell specific-chondroitin sulfate proteoglycan expression during CNS morphogenesis in the chick embryo

There is increasing evidence that proteoglycans, particularly chondroitin sulfate proteoglycans (CSPGs), are integral components in the assembly of the extracellular matrix during early stages of histogenesis. The differential expression of several CSPGs in the developing CNS has raised questions on their origin, phenotype (chemical and structural characteristics), regulation of expression and function. The S103L monoclonal antibody has been an invaluable specific reagent to identify and study a large and abundant CSPG in embryonic chick brain. In the present study we demonstrate that during embryogenesis of the chick CNS, the S103L CSPG (B-aggrecan) is synthesized by neurons of all major neuronal cell types but not by astrocytes, is developmentally regulated, and is associated predominantly with neuronal somata, suggesting that neuronal-specific regulatory mechanisms control the expression of the S103L CSPG in culture. Neurons also exhibit differential expression of glycosaminoglycan type (i.e., KS) and sulfation patterns on different CSPGs when compared to astrocytes, meningial cells or chondrocytes, implying the existence of additional, cell type-specific modes of regulation of the final CSPG phenotype (chemical and structural posttranslational characteristics). A specific temporal pattern of expression of the S103L-CSPG was observed which may contribute to conditions that induce or stabilize specific cell phenotypes during CNS development. In contrast, the other major CSPG in the CNS recognized by the HNK-1 antibody, is synthesized by all cell types of different cell lineages over the entire embryonic period, suggesting a more global cell maintenance function for this CSPG.

Chondrocyte differentiation

Data obtained while investigating growth plate chondrocyte differentiation during endochondral bone formation both in vivo and in vitro indicate that initial chondrogenesis depends on positional signaling mediated by selected homeobox-containing genes and soluble mediators. Continuation of the process strongly relies on interactions of the differentiating cells with the microenvironment, that is, other cells and extracellular matrix. Production of and response to different hormones and growth factors are observed at all times and autocrine and paracrine cell stimulations are key elements of the process. Particularly relevant is the role of the TGF-beta superfamily, and more specifically of the BMP subfamily. Other factors include retinoids, FGFs, GH, and IGFs, and perhaps transferrin. The influence of local microenvironment might also offer an acceptable settlement to the debate about whether hypertrophic chondrocytes convert to bone cells and live, or remain chondrocytes and die. We suggest that the ultimate fate of hypertrophic chondrocytes may be different at different microanatomical sites.

Murine monoclonal antibodies recognizing rabbit proteoglycans

Alterations in the structure and composition of sulfated proteoglycans are found in aging and osteoarthritic rabbits. Monoclonal antibodies (mAB) recognizing specific epitopes of rabbit cartilage proteoglycans would be useful in documenting proteoglycan changes during pathophysiological responses resulting in osteoarthritic pathology in rabbit synovial joints after partial medial meniscectomy. To this point, Balb/c mice were immunized with rabbit proteoglycan (fraction A1D1D1) extracted from xiphoid process. Murine spleen cells were used to prepare hybridomas by fusion with the tumor cell line SP 2/0-Ag 14. Nine mAbs were found to bind to A1D1D1 in a solid phase radioimmunoassay. Binding curves, utilizing A1D1D1 as ligand, resulted in the assignment of mAbs to 3 classes - high, moderate and poor binding mAbs. Binding avidity was independent of immunoglobulin subclass. A1D1D1 was digested with trypsin, chromatographed on DEAE-cellulose and tryptic peptides further resolved by dissociative CsCl density gradient centrifugation. The mAbs were studied in detail utilizing competitive inhibition assays of the resolved peptide fragments. Three types of antigenic fine specificity were observed; a mAb (2G2) which recognized a recurrent epitope on the native A1D1D1, a mAb (2E9) which recognized a single protein epitope, in that it bound to a tryptic peptide that contained a high gluNH2:galNH2 and a mAb (6C9) which preferentially recognized a recurring epitope on heat-treated (50 degrees C minutes) A1D1D1. In this analysis, the epitopes of these mAbs appear to be associated with the core protein since only one mAb (2C7) was competitively inhibited from binding to native A1D1D1 by glycosaminoglycans, hyaluronic acid and oligosaccharides of hyaluronic acid. Direct immunofluorescence staining of rabbit hip, shoulder and knee cartilage showed a differential staining pattern of extracellular matrix with the various mAbs. FITC-2G2 stained the interterritorial matrix intensely; and also the perilacunae zones, whereas FITC-2E9 and FITC-6C9 appeared restricted to the perilacunae regions.

Monoclonal antibodies to proteokeratan sulfate of rabbit corneal stroma

Hybridomas were developed that secreted monoclonal antibodies against two proteokeratan sulfates (PKS) from rabbit corneal stroma. A total of 28 antibodies were isolated, all of the IgG type with kappa light chains. All were found to react with both PKSs. As judged by immunohistochemical staining, none of them reacted with scleral or conjunctival components, nor with sections of skin, but all reacted with nasal cartilage. When tested by enzyme-linked immunosorbent assays, against components of the proteoglycans, all of the antibodies reacted with keratan sulfate-peptide (isolated from papain digests of PKS or of cartilage proteoglycan), and all but two reacted with oligosaccharide-containing protein cores (prepared by keratanase treatment of PKS). Reactivity with cores was probably due to residual portions of the keratan sulfate chains since the endogenous oligosaccharide-peptides (non-sulfated, non-keratan sulfate oligosaccharides isolated after papain digestion of PKS) were not active. None of the antibodies reacted with protein cores made by removal of carbohydrate by hydrolysis with trifluoromethanesulfonic acid. All except one reacted with fragments of keratan sulfate (made by keratanase digestion). These observations are evidence for structural requirements at three different levels of completeness of the antigen for recognition among the various antibodies. In addition, none of the antibodies reacted immunohistochemically with macular dystrophic corneas, confirming the finding of others that the defect lies in the keratan sulfate portion of the proteoglycans.

Production and characterization of monoclonal antibodies to bovine skin proteodermatan sulfate

To study the molecular structure and function of bovine skin proteodermatan sulfate, on a determinant by determinant basis, several monoclonal antibodies to this molecule have been produced and characterized. Based on the results of a preliminary immunogenetic analysis of 4 inbred mouse strains, SJL/J (H-2s) mice were immunized for the fusions. Ten hybridomas were produced and the monoclonal antibodies from four of these were selected for further investigation. Employing an ELISA inhibition assay, none showed any detectable affinity for bovine collagen types I, II, III, or IV, bovine fibronectin or chondroitin or dermatan sulfate glycosaminoglycans. Each monoclonal antibody bound the chondroitinase ABC-derived protein core and none was significantly inhibited by proteinase digests of the intact molecule suggesting that the epitope of each contains a protein component. The results of competitive binding ELISA assays and immunoblots of the cyanogen bromide cleavage products of proteodermatan sulfate indicate that the 4 antibodies recognize at least 3 distinct antigenic determinants on this molecule. Immunohistochemical methods located the antigen in the dermis of bovine skin and revealed that a change in proteodermatan sulfate distribution occurs during skin development.

Radioimmunoassay of proteoglycans

Human articular cartilage proteoglycan monomers (PG) were purified and used for developing a radioimmunoassay. Its analytical sensitivity is 0.6 ng/tube and its clinical sensitivity is 20 microliter/tube for serum and 0.12 microliter/tube for synovial fluid. The intra- and between-assay variation coefficient are less than 10 and 20%, respectively, in the linear part of the curve. There is a complete cross reaction with costal, vertebral disk and tracheal cartilage PGs and the PGs extracted from vein and artery. Concerning the latter, inhibition curves are not parallel. No cross reaction exists with PGs from various fetal tissues and small PGs from bone. However, large PGs from bone produce a weak cross reaction. Furthermore, the assay is species specific since cartilage PGs from dog, rat, chicken and calf embryos either do not or weakly cross react in the assay. Other constituents of cartilage: type II collagen, fibronectin, chondroitin sulfate and hyaluronic acid do not interfere with the assay. The antigenic determinants are localized on the protein core of the PG, as shown by the lack of cross reaction with glycosaminoglycans and PG treatment with various enzymes.

Cell-free translation of messenger RNA for chondroitin sulphate proteoglycan core protein in rat cartilage

Total RNA was extracted from the cartilage tissues rat Swarm chondrosarcoma, neonatal-rat breastplate and embryonic-chicken sterna and translated in wheat-germ cell-free reactions. The core protein of the chondroitin sulphate proteoglycan subunit was identified among translation products of rat mRNA by its apparent Mr of 330 000 and by its immunoprecipitation with specific antisera prepared against rat or chicken proteoglycan antigens. The apparent Mr of the rat proteoglycan core protein is 8000-10000 less than that of the equivalent chicken cartilage core-protein product.

Immunofluorescence studies of chondroitin sulfate proteoglycan biosynthesis: the use of monoclonal antibodies

Several monoclonal antibodies which recognize different antigenic determinants of chondroitin sulfate proteoglycan were used to study chondroitin sulfate proteoglycan biosynthesis in chicken chondrocyte cultures. The intracellular sites of synthesis and processing and extracellular deposition in matrix were localized by double immunofluorescence reactions. One rat monoclonal antibody, S103L , which recognizes an antigenic determinant of the core protein of the chicken cartilage chondroitin sulfate proteoglycan monomer, was used to identify both extracellular chondroitin sulfate proteoglycan and intracellular compartments containing chondroitin sulfate proteoglycan precursors. Intracellular staining with S103L was localized to perinuclear regions, and, in some chondrocytes, to a few other cytoplasmic vesicles as well. When chondrocytes were not fed for several days, intracellular chondroitin sulfate proteoglycan precursors were accumulated in larger compartments distributed throughout the cytoplasm. Polyclonal chondroitin sulfate proteoglycan antibodies displayed similar staining characteristics. In contrast, several of the monoclonal antibodies, including the rat monoclonals S11D and P100D , and the mouse monoclonals 1-B-5, 3-B-3 and 9-A-2, did not recognize native chondroitin sulfate proteoglycan, but reacted only with chondroitinase ABC-digested (and/or hyaluronidase-digested) chondroitin sulfate proteoglycan. These antibodies were particularly useful in the demonstration of the extracellular codistribution of chondroitin sulfate proteoglycan with either type II collagen or fibronectin. In other experiments, the monoclonal antibodies to chondroitin sulfate proteoglycan served to demonstrate that the perinuclear subset of intracellular compartments is uniquely involved in the addition of chondroitin sulfate oligosaccharides to the chondroitin sulfate proteoglycan core protein. Lastly, using the mouse monoclonal 5-D-4, which recognizes keratan sulfate determinants, the perinuclear region was identified as the site for keratan sulfate addition. Results suggest heterogeneity of keratan sulfate synthesis at the level of individual chondrocytes, even for cells apparently containing equivalent amounts of intracellular chondroitin sulfate proteoglycan.

Localization of antigenic components in proteoglycan aggregate of bovine nasal cartilage

Proteoglycans and glyco(link)proteins are demonstrated in the cartilage matrix using immunohistochemical reactions, ruthenium red staining and concanavalin A-peroxidase procedure. Specific antibodies against proteoglycan monomers revealed a loose matrix structure in the interterritorial area of nasal cartilage. Thin filaments of 49-87 nm in length with a knob on one end corresponding to the protein core of proteoglycan monomers were found in irregular contacts with collagen fibres. Following hyaluronidase digestion the immunohistochemical reactions became more intense, and the matrix structure is suggestive of a network of single filaments which are presumably coupled together longitudinally at the sites of small matrix granules. These matrix granules proved to be glyco(link)proteins of proteoglycan aggregate. Immunohistochemical reactions combined with other methods can reveal an in situ structure of proteoglycan aggregate of hyaline cartilage, which contributes substantially to what has been known about the proteoglycan aggregates on the basis of physico-chemical data and has been verified in monomolecular electron microscopic specimens. The enzymatic treatments of cartilage slices suggest that some of the partially digested proteoglycan monomers are required to be present for the preservation of the structural integrity of cartilage tissue.

Immunological methods for the detection and determination of connective tissue proteoglycans

In this paper we report the use of immunological methods for specifically detecting and determining proteoglycan in cartilage and other connective tissues. Antibodies (polyclonal and monoclonal) have been raised against specific components of cartilage proteoglycan aggregates (i.e., proteoglycan monomer and link protein). Radioimmunoassay procedures and immunohistochemical procedures have been developed and used to demonstrate the occurrence of cartilage-like proteoglycan and link protein in bovine aorta. Similarly, immunofluorescent studies have been used to analyze proteoglycan distribution in skin. Using antibodies specific for chondroitin-4-sulfated proteoglycan, their presence was demonstrated in dermal connective tissue and connective tissue surrounding nerve and muscle sheaths. However, chondroitin-4-sulfated proteoglycan was completely absent in the epidermis of skin and areas surrounding invaginating hair follicles. These immunological procedures are currently being used to complement conventional biochemical analyses of proteoglycans found in different connective tissue matrices.